Overview of Glp 1 Receptor Agonists Glp 1Ras Cardiovascular Actions

GLP-1 receptor agonists ( GLP-1RAs ): cardiovascular actions and therapeutic potential Exendin-4 was originally found in the saliva of the venomous lizards whose synthetic version is exenatide. Exendin-4 inhibits the remodeling in the remote myocardium of rats following acute MI by attenuating β-catenin activation and activating glycogen synthase kinase-3, β-arrestin-2 and protein phosphatase ...

Background Glucagon-like peptide-1 receptor agonists ( GLP-1RAs ) are widely used for the management of type 2 diabetes and obesity, yet their long-term cardiovascular effects in high-risk populations continue to be actively evaluated. Given emerging evidence of both metabolic and direct cardiovascular actions , a comprehensive synthesis of cardiovascular outcome trial data is required to clarify ...
PDF GLP

GLP-1 is a gut-derived insulin agonist with the ability to suppress glucagon release and stimulate insulin secretion through targeting α-cells and β-cells, respectively [5]. Likewise, GLP-1RAs can lower postprandial glycemia predominantly by slowing gastric emptying and promoting weight loss [6, 7]. GLP-1RAs may improve endothelial cell function via anti-inflammatory and vasodilatory ...
Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists ( GLP-1RAs ), including reduced cardiovascular mortality, lower rates of myocardial infarction, and lower rates of stroke. The cardiovascular benefits observed following GLP-1RA treatment could be secondary to ...

Useful Notes on Glp 1 Receptor Agonists Glp 1Ras Cardiovascular Actions
Glucagon-like peptide-1 receptor agonists ( GLP-1RAs ) have garnered considerable attention, as they not only regulate blood glucose but also play a vital role in safeguarding the cardiovascular system. Recent research shows that metabolic reprogramming is a key mechanism for the cardioprotective effects of GLP-1RAs .
Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) provide proven cardiovascular benefits in type 2 diabetes mellitus (T2DM) and heart failure, but their effects in patients with peripheral artery disease (PAD) remain unclear. PAD is common in T2DM and increases the risk of adverse cardiovascular and limb outcomes. This meta-analysis assessed the impact of GLP-1 RAs on cardiovascular and ...

Overview of Glp 1 Receptor Agonists Glp 1Ras Cardiovascular Actions
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists now serve as therapeutic agents for cardiovascular diseases (CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM). This review combines molecular mechanisms with clinical evidence to demonstrate how GLP-1 agonists help lower cardiovascular risk for conditions, including atherosclerosis, heart failure, stroke, and ...
Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) have instigated a paradigm shift in the management of cardiometabolic disease. Initially developed for glycemic control in type 2 diabetes, their therapeutic role has expanded dramatically following the demonstration of robust cardiovascular benefits in large-scale clinical trials. This review provides a comprehensive synthesis of the ...

Cardiovascular Effects and Tolerability of GLP
Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined.








Glucagon-like peptide-1 ( GLP-1 ) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ago...